Analysis: AMAG Pharmaceuticals (NASDAQ:AMAG) Stock Target Raised Today
In a note revealed to clients by Leerink Swann on 10 December, the firm, AMAG Pharmaceuticals (NASDAQ:AMAG), had their target PPS lowered to $45.00. Analusts presently have a solid Outperform rating on the stock.
From a total of 7 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 71% of the ratings are positive. The highest target price is $80 while the lowest target price is $43. The mean of all analyst targets is $62.86 with a 141.24% above today’s ($27.91) stock price. AMAG Pharmaceuticals was the topic of 8 analyst reports since August 18, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on November 19 with “Hold” rating. Zacks downgraded AMAG stock in a recent report from August 19 to “Strong-Buy” rating.
Approximately 441,839 shares of stock traded hands. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 51.52% since May 7, 2015 and is downtrending. It has underperformed by 49.58% the S&P500.
The overall sentiment of institutions has increased to 1.55 in Q2 2015. Its up 0.23, from 1.32 in 2015Q2. The ratio is positive, as 45 institutions have sold all the shares of AMAG Pharmaceuticals, Inc. that they owned while 46 funds have taken shares off the table. 50 funds have purchased shares for the first time while 91 added to their positions. These institutions now hold 53.70 million shares or 39.00% more than the 38.63 million shares they owned in 2015Q2.
The Fund Palo Alto Investors Llc currently is holding shares equating to 5.31% of its total portfolio in AMAG Pharmaceuticals, Inc. representing a total of 2.78 million shares. Another fund,Opaleye Management Inc., is holding a total of 200,000 shares equating to 3.91% of their holdings. Additionally, Ironwood Investment Management Llc has a 108,423 share stake in AMAG Pharmaceuticals, Inc. which represents 1.58% of their total portfolio. The Fund, Ashford Capital Management Inc, based out of Delaware, has also built up a stake in the stock, which represents a total of 1.53% of their total portfolio. Finally Endurant Capital Management Lp, a fund which is based in the state of California reported a total holdings of 94,100 shares.
Insider activity is a very important aspect to track on any stock. Going back to June 5, 2015, shareholders of AMAG Pharmaceuticals, Inc. have witnessed 0 buys, and a total of 4 sales equating to a net activity of approximately $2.70 million . Heiden William K sold 2,000 shares worth approximately $79,380. Thomas Frank E sold 15,000 shares worth approximately $1.00 million. Wilson Kenneth H sold 5,388 shares worth approximately $370,533.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $995.86 million. The Firm focuses on maternal health, anemia and cancer supportive care. It has 6 P/E ratio. The Firm markets Makena , Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.” Get a free copy of the Zacks research report on AMAG Pharmaceuticals, Inc. (AMAG).